Shenzhen Fbtech Electronics Ltd. et al. v. LithiumHub Technologies, LLC

IPR2025-00822

LithiumHub Technologies and two Shenzhen firms settled IPR2025‑00822 concerning a solid‑state lithium battery patent, seeking dismissal of the proceeding.

Jurisdiction
US PTAB
Case Number
IPR2025-00822
Filing Date
4 January 2025
Outcome
terminated or settled

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Shenzhen Fbtech Electronics Ltd. et al. vs LithiumHub Technologies, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentIPR2024-00996

Anker Innovations Ltd.vsPowermat Technologies Ltd.

Anker Innovations and Powermat Technologies settled their IPR dispute over wireless charging patents, leading the PTAB to terminate the proceeding. No merits were decided.

patentIPR2024-00375

Askeladden L.L.C.vsIntercurrency Software LLC

Askeladden L.L.C. successfully petitioned to institute IPR proceedings against Intercurrency Software LLC's '863 patent, challenging all twelve claims based on obviousness (103). The Board found that the Petitioner demonstrated a reasonable likelihood of prevailing with respect to at least one claim challenged in the Petition.

patentIPR2024-00122

US Conec Ltd.vsSenko Advanced Components, Inc.

Petitioner US Conec Ltd. challenges U.S. Patent No. 11,061,190 by asserting obviousness (Section 103) over multiple combinations of prior art references including Nakagawa, Raven, Veatch, Connelly, and Cline. The petitioner argues that the combination of these references would have been predictable to a POSITA, while also contesting the applicability of § 325(d) discretionary denial.

patentIPR2025-00106

Jumio CorporationvsFaceTec, Inc.

The PTAB Director denied Jumio Corp.'s request for review of the institution decision in IPR2025-00106, leaving the institution of FaceTec's patent intact.

patentIPR2025-00176

Samsung Bioepis Co., Ltd.vsRegeneron Pharmaceuticals, Inc.

Samsung Bioepis sought to invalidate numerous claims of Regeneron Pharmaceuticals' ophthalmic formulations using grounds of obviousness (103). The PTAB denied institution based on a holistic Fintiv analysis, citing significant overlap with ongoing district court and MDL proceedings.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call